학술논문
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial
Document Type
Article
Author
Roussel, Murielle; Moreau, Philippe; Hebraud, Benjamin; Laribi, Kamel; Jaccard, Arnaud; Dib, Mamoun; Slama, Borhane; Dorvaux, Véronique; Royer, Bruno; Frenzel, Laurent; Zweegman, Sonja; Klein, Saskia K; Broijl, Annemiek; Jie, Kon-Siong; Wang, Jianping; Vanquickelberghe, Veronique; de Boer, Carla; Kampfenkel, Tobias; Gries, Katharine S; Fastenau, John; Sonneveld, Pieter
Source
In The Lancet Haematology December 2020 7(12):e874-e883
Subject
Language
ISSN
2352-3026